These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887 [TBL] [Abstract][Full Text] [Related]
5. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Yajima N; Yamanaka R; Mine T; Tsuchiya N; Homma J; Sano M; Kuramoto T; Obata Y; Komatsu N; Arima Y; Yamada A; Shigemori M; Itoh K; Tanaka R Clin Cancer Res; 2005 Aug; 11(16):5900-11. PubMed ID: 16115932 [TBL] [Abstract][Full Text] [Related]
6. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952 [TBL] [Abstract][Full Text] [Related]
7. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526 [TBL] [Abstract][Full Text] [Related]
11. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Noguchi M; Uemura H; Naito S; Akaza H; Yamada A; Itoh K Prostate; 2011 Apr; 71(5):470-9. PubMed ID: 20878951 [TBL] [Abstract][Full Text] [Related]
12. [Peptide vaccination for castration-resistant prostate cancer]. Koga N; Noguchi M Nihon Rinsho; 2014 Dec; 72(12):2147-51. PubMed ID: 25518349 [TBL] [Abstract][Full Text] [Related]
14. The immunotherapy of prostate and bladder cancer. Totterman TH; Loskog A; Essand M BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528 [TBL] [Abstract][Full Text] [Related]
15. [Personalized peptide vaccination]. Itoh K; Takahashi R; Yoshitomi M; Terasaki M; Noguchi M Nihon Rinsho; 2012 Dec; 70(12):2118-23. PubMed ID: 23259383 [TBL] [Abstract][Full Text] [Related]
16. [Current status and prospects of cancer vaccine therapy]. Mine T; Terazaki Y; Itoh K Nihon Rinsho; 2011 Sep; 69(9):1651-6. PubMed ID: 21922769 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045 [TBL] [Abstract][Full Text] [Related]
18. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization. Kogan Y; Halevi-Tobias K; Elishmereni M; Vuk-Pavlović S; Agur Z Cancer Res; 2012 May; 72(9):2218-27. PubMed ID: 22422938 [TBL] [Abstract][Full Text] [Related]
19. Vaccines for glioblastoma and high-grade glioma. Wheeler CJ; Black KL Expert Rev Vaccines; 2011 Jun; 10(6):875-86. PubMed ID: 21692706 [TBL] [Abstract][Full Text] [Related]
20. Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients. Bins A; Mallo H; Sein J; van den Bogaard C; Nooijen W; Vyth-Dreese F; Nuijen B; de Gast GC; Haanen JB J Immunother; 2007; 30(2):234-9. PubMed ID: 17471170 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]